IP Library Granted Patent US 10,864,322
Granted Patent B2
US 10,864,322 · App. 15/848,163 · Granted Dec 15, 2020

System and method for mitigating risk in automated medicament dosing

Inventors: Sean Saint (San Diego, CA); Michael Rosinko (Anaheim, CA)
Assignee: Tandem Diabetes Care, Inc.
A61M5/1723A61M5/14244G06F19/3468G16H20/17G16H40/63G16H40/67G16H50/20G16H50/70A61M2005/14208A61M2205/3523A61M2205/502A61M2205/52A61M2209/01A61M2230/005A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,322
App. No.
15/848,163
Granted
Dec 15, 2020
Kind
B2
Abstract

A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.

Claims (37)

1. A portable infusion system, comprising:

a delivery mechanism adapted to facilitate delivery of a medicament to a user;

a memory adapted to store parameters relating to the delivery of the medicament;

a communications device adapted to receive information from a continuous glucose monitor;

a processor functionally linked to the delivery mechanism, the memory and the communications device, the processor configured to:

obtain the information from the continuous glucose monitor;

store in a memory a threshold relating to predicted accuracy of the continuous glucose monitor after which automatic adjustment of the delivery of the medicament based on the information from the continuous glucose monitor is not permitted;

monitor the information received from the continuous glucose monitor;

determine that the threshold has been reached;

disable automatic adjustment of the delivery of the medicament based on the information from the continuous glucose monitor if it is determined that the threshold has been reached.

2. The portable infusion system of claim 1 , wherein the threshold is set as an amount of time that has elapsed since a most recent calibration of the continuous glucose monitor.

3. The portable infusion system of claim 2 , wherein the processor is configured to determine that the continuous glucose monitor has been calibrated and re-enable automatic adjustment after determining that the continuous glucose monitor has been calibrated.

4. The portable infusion system of claim 3 , wherein the processor automatically re-enables automatic adjustment after determining that the continuous glucose monitor has been calibrated.

5. The portable infusion system of claim 2 , wherein the amount of time is 12 hours.

6. The portable infusion system of claim 1 , wherein the threshold is set as a maximum predicted error of the continuous glucose monitor.

7. The portable infusion system of claim 1 , wherein the threshold is set as a maximum difference between a blood glucose level at a most recent calibration of the continuous glucose monitor and a current estimated blood glucose level of the continuous glucose monitor.

8. The portable infusion system of claim 1 , wherein the processor is a part of an ambulatory infusion pump that includes the delivery mechanism.

9. The portable infusion system of claim 1 , wherein the processor is further configured to provide a notification on a user interface that automatic adjustment of the delivery of the medicament has been disabled.

10. The portable infusion system of claim 9 , wherein the user interface is part of an ambulatory infusion pump that includes the delivery mechanism.

11. A portable infusion system, comprising:

a delivery mechanism adapted to facilitate delivery of a medicament to a user;

a memory adapted to store parameters relating to the delivery of the medicament;

a communications device adapted to receive information from a continuous glucose monitor;

a processor functionally linked to the delivery mechanism, the memory and the communications device, the processor configured to:

obtain the information from the continuous glucose monitor;

enable automated dosing during which at least some delivery of the medicament to the user is automatically adjusted based on the information from the continuous glucose monitor;

store a predetermined time limit for automated dosing, the predetermined time limit determined based on a predicted reliability of the information from the continuous glucose monitor;

disable automated dosing upon determining that the predetermined time limit has been reached.

12. The portable infusion system of claim 11 , wherein the predetermined time limit is based on a time since a most recent calibration of the continuous glucose monitor.

13. The portable infusion system of claim 12 , further comprising:

receiving an indication that the continuous glucose monitor has been calibrated; and

resetting the predetermined time limit after receiving the indication that the continuous glucose monitor has been calibrated.

14. The portable infusion system of claim 12 , wherein the processor is configured to determine that the continuous glucose monitor has been calibrated and re-enable automated dosing after determining that the continuous glucose monitor has been calibrated.

15. The portable infusion system of claim 14 , wherein the processor automatically re-enables automated dosing after determining that the continuous glucose monitor has been calibrated.

16. The portable infusion system of claim 11 , wherein the processor is a part of an ambulatory infusion pump that includes the delivery mechanism.

17. The portable infusion system of claim 11 , wherein the processor is further configured to provide a notification on a user interface that automated dosing has been disabled.

18. The portable infusion system of claim 17 , wherein the user interface is part of an ambulatory infusion pump that includes the delivery mechanism.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2024
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: TANDEM DIABETES CARE, INC.
Reel/Frame 066880/0918 →
SECURITY INTEREST Recorded May 25, 2022
From: TANDEM DIABETES CARE, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060179/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: SAINT, SEAN; ROSINKO, MICHAEL J.
To: TANDEM DIABETES CARE, INC.
Reel/Frame 044445/0523 →
Continuity (3)
Continuation 14479994 · Sep 8, 2014
Provisional Application 61874428 · Sep 6, 2013
Related Publication 20180110921A1 · Apr 26, 2018
Cited By (11)
US 1,127,405 US 1,128,266 US 12,204,889 US 12,251,536 US 12,318,578 US 12,431,104 US 12,465,686 US 12,551,618 US 12,564,677 US 12,567,494 US 12,653,968